30 Repurposed and Alternative Cancer Interventions: Evidence-Ranked Analysis (2026 Clinical Update)
Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Source: Nature 2024
Introduction
Most mainstream guides to “alternative cancer treatments”—including the widely cited Mayo Clinic overview—focus primarily on supportive and integrative approaches such as acupuncture, massage, meditation, and other mind-body therapies. These approaches can complement conventional oncology care, but they are fundamentally different from therapies being investigated for direct anticancer or antitumor activity.
This article takes a broader approach. It examines 30 interventions spanning approved immunotherapies, repurposed drugs, lifestyle strategies, immune-modulating approaches, and experimental compounds, and ranks them according to the quality, consistency, and volume of available evidence. The goal is to provide patients, caregivers, and clinicians with a structured reference for understanding the evolving cancer-treatment landscape.
Think of cancer treatment as a chessboard: no single piece wins the game alone. Outcomes may depend on how different therapeutic strategies are coordinated to address the biology of an individual cancer. The interventions with the strongest supporting evidence should therefore be considered first, as part of a comprehensive treatment plan developed with qualified oncology professionals.
A landmark review of randomized controlled trials (RCTs) in oncology found that many newly approved cancer drugs produce relatively modest improvements in median overall survival, often measured in months rather than years. Some analyses have estimated median gains of approximately 2–4 months for certain newly approved therapies. (58, 59)
Targeting specific genetic alterations has nevertheless transformed the treatment of several cancers and has produced some of the most important advances in modern oncology. Precision therapies can deliver substantial and sometimes durable responses in patients whose tumors harbor actionable molecular alterations.
However, important limitations remain:
- Many responses are partial rather than complete.
- Responses can be temporary.
- Acquired or intrinsic drug resistance is common.
- A mutation-centered approach does not fully address the biological complexity and heterogeneity of advanced cancer.
For these reasons, the future of oncology will likely depend increasingly on combination therapies, biomarker-guided treatment, and personalization. Rather than relying on a single target or pathway, researchers are investigating combinations designed to address multiple mechanisms of tumor growth, immune evasion, metabolism, and treatment resistance.
Repurposed drugs may have an important role in this research landscape. Because many have established safety profiles, known pharmacology, and potentially lower development costs, they may offer opportunities to investigate additional therapeutic combinations more efficiently and affordably. However, stronger evidence from well-designed clinical trials is still needed before such approaches can be considered established cancer treatments.
Methodology: Evidence Tier Framework
Evidence quality hierarchy. Meta-analyses of RCTs occupy the apex; preclinical studies form the base.
Interventions are organised into four evidence tiers:
| Tier | Evidence Quality | Examples |
|---|---|---|
| Tier 1 — Strong | Meta-analyses of RCTs; approved clinical indications; landmark guideline-changing trials | Aspirin (PIK3CA-mutant CRC), Exercise, Metformin, Statins, Cimetidine (CRC) |
| Tier 2 — Moderate | Individual RCTs; systematic reviews with clinical trial data; prospective cohorts | BCG (bladder cancer), Low Dose Naltrexone (LDN), Propranolol, Vitamin D3, Omega-3, Vitamin C (IV), Hyperthermia, Melatonin |
| Tier 3 — Emerging | Observational studies, retrospective analyses, small clinical series, case series with mechanistic support | Ivermectin, Benzimidazoles, Curcumin, Green Tea (EGCG), Berberine, Disulfiram, Itraconazole, Sildenafil/PDE5i, Glucose/Keto, Methylene Blue |
| Tier 4 — Experimental | Primarily preclinical (cell/animal); limited or no human data; case reports only | DMSO, Ashwagandha, HBOT, Gerson Therapy, Hydralazine (GBM), Stress/Sleep/Sunshine |
Quick Reference: All 30 Interventions at a Glance
| # | Intervention | Tier | Best Evidence Context | Human Trials? |
|---|---|---|---|---|
| 1 | Aspirin + COX-2 Inhibitors | Tier 1 | PIK3CA-mutant CRC (ALASCCA RCT, NEJM 2025) | Yes — RCT + Guideline |
| 2 | Exercise | Tier 1 | Multi-cancer survival improvement | Yes — Meta-analyses |
| 3 | Metformin | Tier 1 | Multiple cancers; metabolic suppression | Yes — RCTs ongoing |
| 4 | Statins | Tier 1 | Colorectal, breast, prostate cancers | Yes — Meta-analyses |
| 5 | Cimetidine (H2 Blockers) | Tier 1 | Colorectal cancer (Cochrane meta-analysis) | Yes — 6 RCTs pooled |
| 6 | BCG Immunotherapy | Tier 2 | Bladder cancer (non-muscle invasive) — narrow indication | Yes — Approved |
| 7 | Low Dose Naltrexone (LDN) | Tier 2 | Multiple cancers; immune modulation; OGF axis | Yes — Small RCTs + systematic reviews |
| 8 | Propranolol | Tier 2 | Perioperative use; multiple cancers | Yes — RCTs + meta-analysis |
| 9 | Vitamin D3 | Tier 2 | Cancer risk reduction; survival support | Yes — RCTs |
| 10 | Omega-3 Fatty Acids | Tier 2 | Anti-cachexia; adjunctive chemo support | Yes — RCTs |
| 11 | Hyperthermia | Tier 2 | Combined with chemo/RT; melanoma, sarcoma | Yes — Multicenter RCTs |
| 12 | Melatonin | Tier 2 | Chemo adjunct; quality of life | Yes — Multiple RCTs |
| 13 | High-dose Vitamin C (IV) | Tier 2 | Adjunct to chemo; pharmacologic dosing | Yes — Phase I/II trials |
| 14 | Ivermectin | Tier 2 | TNBC (Phase I/II trial active); multiple cancers | Yes — Phase I/II trials |
| 15 | Benzimidazoles (Fenbendazole/Mebendazole/Albendazole) | Tier 2 | Multiple cancers; case series + preclinical | Yes — Phase I/II trials |
| 16 | Tumor Treating Fields (TTFields) New | Tier 2 | Glioblastoma (EF-14 Phase III RCT); mesothelioma (FDA-approved) | Yes — Phase III RCT + Approved |
| 17 | Curcumin (Nanocurcumin) | Tier 3 | Anti-inflammatory; adjunct therapy | Limited — Small trials |
| 18 | Green Tea (EGCG) | Tier 3 | Cancer prevention; epidemiological data | Limited — Observational |
| 19 | Berberine | Tier 3 | Metabolic targeting; colorectal, breast | Limited — Small trials |
| 20 | Disulfiram | Tier 3 | GBM; NSCLC; cancer stem cells | Yes — Phase I/II trials |
| 21 | Itraconazole | Tier 3 | Prostate, lung, basal cell; Hedgehog signalling | Yes — Phase II trials |
| 22 | Sildenafil/PDE5 Inhibitors | Tier 3 | Chemo sensitisation; immune modulation | Limited — Small trials |
| 23 | Glucose Management + Keto Diet + GLP-1 | Tier 3 | Metabolic oncology; insulin reduction | Limited — Observational |
| 24 | Methylene Blue | Tier 3 | Photodynamic therapy; ovarian, GBM | Yes — Systematic review (PDT) |
| 25 | DMSO | Tier 4 | Chemo potentiator; experimental | Anecdotal only |
| 26 | Ashwagandha | Tier 4 | Immune support; anti-proliferative | Minimal |
| 27 | HBOT | Tier 4 | Press-Pulse metabolic strategy | Very limited |
| 28 | Gerson Therapy | Tier 4 | Nutritional/detox; historical only | None robust |
| 29 | Hydralazine (GBM) | Tier 4 | Glioblastoma; cell studies only | Not yet |
| 30 | Stress Reduction, Sleep, Sunshine | Tier 4 | Immune support; lifestyle baseline | Indirect |
- Tier 1: Strong Clinical Evidence
- Tier 2: Moderate Clinical Evidence
- Tier 3: Emerging / Clinical Series Evidence
- Tier 4: Experimental / Preclinical Evidence
- Anticancer Nutrition: The Dietary Foundation
- Lifestyle Foundation: Stress, Sleep & Sunshine
- Discussion: Where the Field Is Heading
- Frequently Asked Questions
- Using AI to Personalize This Framework
- Conclusion
- References
Tier 1: Strong Clinical Evidence
These four interventions have the most robust human data — including meta-analyses of randomized controlled trials or landmark trials that have directly influenced clinical guidelines. BCG sits in Tier 2 despite its approved status, because its evidence base is narrow (single cancer type, single administration route) compared with the multi-cancer, meta-analysis-supported interventions below.
1. Aspirin & COX-2 Inhibitors (Celecoxib) TIER 1 · RCT + GUIDELINE
Aspirin illustrates what successful repurposing can look like when a biological hypothesis is tested in a biomarker-selected randomized clinical trial.
The ALASCCA trial (NCT02647099) is the most clinically important recent development in this space. Across 33 hospitals in Sweden, Denmark, Finland, and Norway, 3,508 patients with stage I–III colorectal cancer were screened for PI3K-pathway alterations; 626 with a qualifying mutation were randomized to 160 mg aspirin or placebo daily for three years post-surgery. Three-year results, presented at the 2025 ASCO Gastrointestinal Cancers Symposium and later published in the New England Journal of Medicine, showed aspirin reduced disease recurrence by 51% in patients with PIK3CA exon 9/20 mutations (HR 0.49) and by 58% in patients with other PIK3CA/PIK3R1/PTEN pathway alterations — alterations present in roughly 37% of trial participants, expanding the addressable population to more than a third of localized CRC. The NCCN has since incorporated PIK3CA-pathway testing into its guidelines to identify candidates for adjuvant aspirin, making it one of the first widely available drugs formally integrated into precision-oncology guidance.
Separately, a Cardiff University review (Br J Cancer, 2023) of 118 observational studies in roughly one million cancer patients found daily low-dose aspirin associated with a 21% reduction in all-cause cancer mortality, with particularly strong signals for colorectal (27%), gastric (36%), and hepatobiliary (38%) cancers.
For celecoxib, a 2009 landmark study found patients taking COX-2 inhibitors for six or more months post-diagnosis were nearly 80% less likely to develop bone metastases in breast cancer. Ben Williams' long-term glioblastoma survival (diagnosed 1995) famously included celecoxib as part of his off-label drug cocktail.
🔗 Read more: ALASCCA Trial Results — Aspirin in PIK3CA-mutant CRC
⚠️ Aspirin increases bleeding risk and is not recommended in patients on anticoagulants without specialist guidance. Celecoxib is contraindicated in severe heart failure.
2. Metformin TIER 1 · MULTIPLE RCTs
Metformin's anticancer potential is one of the most extensively studied areas in repurposed oncology pharmacology. Population studies consistently show reduced cancer incidence and mortality in diabetic patients taking metformin versus other glucose-lowering agents. Its safety profile, low cost, and multi-pathway activity (AMPK activation, mTOR inhibition, reduced circulating insulin/IGF-1) make it a cornerstone of metabolic-oncology protocols.
⚠️ GI side effects are common at initiation. Contraindicated in severe renal impairment (eGFR <30). Long-term use is associated with B12 deficiency — supplement with a B-complex. Do not combine with berberine without blood-glucose monitoring.
3. Statins (Atorvastatin / Simvastatin / Pitavastatin) TIER 1 · META-ANALYSES
Meta-analyses across multiple cancer types show statin use associated with 15–35% reductions in cancer-specific mortality. Pitavastatin is increasingly preferred in oncology protocols for its minimal drug interactions. Statins synergize well with metformin, aspirin, and benzimidazoles in multi-drug repurposing regimens.
🔗 Related: Ivermectin synergy with statins in ovarian cancer (2023 UK/Iraqi study)
4. Cimetidine and H2 Blockers TIER 1 · COCHRANE META-ANALYSIS
Cimetidine is arguably the most underappreciated repurposed drug in oncology. Its survival benefit in colorectal cancer — a 10-year survival rate of 84.6% versus 49.8% in a Japanese long-term cohort — has been echoed across multiple independent studies, and a Cochrane meta-analysis confirms a statistically significant overall survival benefit. The benefit appears specific to cimetidine rather than other H2 blockers, pointing to mechanisms beyond H2-receptor blockade (proposed effects include E-selectin inhibition and immunomodulation).
⚠️ Cimetidine raises plasma levels of propranolol; beta-blocker dosing may need adjustment. It has multiple drug interactions — review carefully with a pharmacist.
Tier 2: Moderate Clinical Evidence
These interventions are supported by individual RCTs, systematic reviews of trial data, prospective cohort studies, Phase I/II data, or approved-indication status within a narrowly defined cancer type. The evidence is meaningful but not yet at the multi-cancer, meta-analysis level of Tier 1.
5. BCG Immunotherapy TIER 2 · APPROVED (SINGLE CANCER TYPE)
BCG provides one of the clearest historical examples of successful repurposing in oncology.
Originally developed as a tuberculosis vaccine, intravesical BCG became an established immunotherapy for selected patients with non-muscle-invasive bladder cancer.
Unlike many experimental repurposing candidates discussed online, BCG is not merely a mechanistic hypothesis or collection of case reports. Its use in appropriate bladder cancer settings is supported by extensive clinical evidence and oncology guidelines.
This distinction matters because it demonstrates the difference between:
- "This drug might have anticancer activity"
- and
- "This drug has become part of established cancer care."
BCG remains the gold-standard adjuvant treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) and is an approved, guideline-recommended immunotherapy. Its Tier 2 placement (rather than Tier 1) reflects this review's framework: Tier 1 requires multi-cancer, meta-analysis-level data. BCG's evidence is deep and unambiguous within its indication — but it applies to one cancer, delivered by one route, under one specialist type.
⚠️ Not suitable for immunocompromised patients or those with active TB. Side effects include bladder irritation and, rarely, systemic BCG infection. Requires urological supervision.
6. Tumor Treating Fields (TTF / Optune) TIER 2 · PHASE III RCTs, APPROVED
Tumor Treating Fields use low-intensity, alternating electric fields delivered via scalp- or body-worn transducer arrays to disrupt mitotic spindle formation and cell division in rapidly dividing tumor cells. TTF is FDA-approved and guideline-recommended for newly diagnosed and recurrent glioblastoma, and for malignant pleural mesothelioma in combination with chemotherapy.
The EF-14 trial (newly diagnosed GBM, TTF + temozolomide vs. temozolomide alone) showed a survival benefit that persisted at five-year follow-up, and the earlier EF-11 trial found TTF non-inferior to chemotherapy in recurrent GBM with a substantially better tolerability profile. The STELLAR trial (malignant pleural mesothelioma, TTF + pemetrexed/platinum chemotherapy, n=80) reported a median overall survival of 18.2 months versus a 12.1-month historical control. Novocure's ongoing pipeline (PANOVA-3 in pancreatic cancer, LUNAR in NSCLC, INNOVATE-3 in ovarian cancer) is extending the approach to additional solid tumors.
⚠️ Requires near-continuous device wear (typically ≥18 hours/day) for benefit, which is a significant lifestyle and adherence burden. Skin irritation under the transducer arrays is common. Not appropriate for patients with certain implanted electronic devices.
7. Hyperthermia (Therapeutic) TIER 2 · MULTICENTER RCTs
Therapeutic hyperthermia raises tumor tissue temperature (typically 40–44°C) via regional, local, or whole-body devices, used as an adjunct to radiotherapy or chemotherapy. Proposed mechanisms include direct thermal cytotoxicity, increased tumor blood flow and oxygenation (improving radiosensitivity), protein denaturation, and enhanced immune-cell trafficking into the tumor. The multicenter ESHO trial of hyperthermia combined with radiotherapy in metastatic melanoma is among the more established randomized data sets in this space, and hyperthermia is used as an adjunct in several European academic centers for defined indications (superficial recurrent breast cancer, cervical cancer, sarcoma).
⚠️ Requires specialized equipment and trained centers; not widely available. Local hyperthermia carries a risk of skin burns; whole-body hyperthermia carries cardiovascular stress risk and requires careful monitoring.
8. Mistletoe Extract (Viscum album) TIER 2 · PHASE I TRIAL + QoL RCTs
Mistletoe extract is among the most widely used complementary therapies in European integrative oncology, typically given by subcutaneous injection. The strongest recent clinical data come from a Johns Hopkins Phase I trial of intravenous mistletoe extract in advanced, treatment-refractory solid tumors (Paller et al., Cancer Research Communications, 2023): 21 patients, a disease control rate of 23.8%, meaningful quality-of-life improvement, and an established Phase II dose. A separate systematic review pooling 30 datasets from 26 publications supports quality-of-life benefit during chemotherapy across the broader (mostly subcutaneous) evidence base. It is important to be precise about what this evidence does and does not show: the subcutaneous RCT literature consistently supports QoL benefit during chemotherapy, but has not demonstrated a survival benefit in rigorous placebo-controlled trials, and the positive IV data are from a small, early-phase, dose-finding study rather than a confirmatory trial.
⚠️ Mistletoe can cause injection-site reactions, fever, and rarely anaphylaxis. It should be sourced and dosed under practitioner supervision, particularly for IV use, which remains investigational outside clinical trials.
9. Low Dose Naltrexone (LDN) TIER 2 · SMALL RCTs + SYSTEMATIC REVIEWS
LDN is one of the most under-investigated compounds in integrative oncology relative to its mechanistic rationale and safety profile. At the low doses used (1.5–4.5 mg), naltrexone does not block opioid receptors continuously — it occupies them transiently for 4–6 hours during sleep, triggering a rebound overshoot in endogenous opioid production. This intermittent upregulation of the opioid growth factor (OGF) pathway is the proposed anti-proliferative mechanism, distinct from the pharmacology of full-dose naltrexone (50 mg) used in addiction medicine.
The foundational research comes from Dr. Ian Zagon's laboratory at Penn State, spanning over three decades and describing the OGF/OGFr pathway's role in regulating tumor-cell proliferation across pancreatic, colorectal, squamous-cell, and hematological cancers. A 2024 systematic review in Cureus pooled data from 16 studies and found consistent signals for improved quality of life and tumor response. A Phase II RCT in pancreatic cancer (NCT04401579) is ongoing.
LDN's safety profile is favorable — at doses below 5 mg, significant adverse effects are rare and typically limited to transient sleep disturbance in the first one to two weeks. It has no known organ toxicity and no significant drug interactions at low doses, apart from full opioid agonists, and costs roughly USD $30–50/month from a compounding pharmacy.
⚠️ Critical contraindication: LDN must not be used with full opioid agonists (morphine, oxycodone, fentanyl, tramadol, codeine, methadone) — it will precipitate acute opioid withdrawal. Patients must be opioid-free for at least 7–10 days before starting. Also avoid with extended-release naltrexone implants (Vivitrol). Requires a compounding-pharmacy prescription, since standard 50 mg naltrexone tablets cannot be reliably split to LDN doses.
🔗 Resources: LDN Research Trust · Phase II Pancreatic Cancer Trial (NCT04401579) · 2024 Systematic Review (Cureus) · Low-Dose Naltrexone for Cancer: Case Series and Human Studies (2026)
10. Propranolol (Beta-Blocker) TIER 2 · RCTs + META-ANALYSIS
The perioperative window — the days around cancer surgery — represents a period of heightened metastatic risk due to surgical stress hormones. Propranolol blunts this by blocking beta-adrenergic signaling. The COMPIT trial's results (50% vs. 12.5% recurrence) are striking, and a 2025 meta-analysis of 31 studies confirms the signal across cancer types. Perioperative propranolol plus etodolac represents one of the more compelling low-cost surgical adjuncts in integrative oncology.
⚠️ Contraindicated in asthma, severe bradycardia, and uncompensated heart failure. Never stop abruptly — taper under medical supervision.
11. Vitamin D3 TIER 2 · RCTs
Vitamin D3 is commonly marketed as a dietary supplement, but cholecalciferol is a biologically active secosteroid precursor converted into hormonally active metabolites that influence numerous physiological processes via the vitamin D receptor, which is why it is included here alongside conventional pharmacological agents.
⚠️ Patients on warfarin need close monitoring before adding vitamin K2. Toxicity is possible at very high doses — check serum levels before high-dose supplementation.
12. Omega-3 Fatty Acids (EPA/DHA) TIER 2 · RCTs
⚠️ Increased bleeding risk at high doses — use caution with anticoagulants. Choose pharmaceutical-grade, mercury-free supplements.
13. Melatonin TIER 2 · MULTIPLE RCTs
⚠️ High-dose melatonin may cause vivid dreams and daytime somnolence. Start low. Potential interaction with immunosuppressants.
14. Ivermectin TIER 2 · PHASE I/II TRIAL ACTIVE
- Cancer types: Triple-negative breast cancer (active trial); leukemia, colorectal, gastric, lung, prostate, ovarian (case series).
- Human evidence: De Castro et al. 2020 (refractory pediatric AML, 1 mg/kg/day); Ishiguro et al. 2022 (12 mg BID); NCT05318469 Phase I/II trial of ivermectin + balstilimab in metastatic TNBC (Cedars-Sinai); 700+ compiled case reports including Stage 4 no-evidence-of-disease (NED) reports — see Ivermectin Cancer Case Reports Compilation.
- Research funding: Florida's state-funded Cancer Innovation Fund allocated $60 million in September 2025 toward research on repurposed generic drugs and nutrition-based cancer prevention, naming ivermectin as one of several agents of interest alongside a broader nutrition and repurposed-generics agenda — not a dedicated ivermectin-only program.
- Mechanism: Proposed multi-pathway activity including T-cell activation and tumor infiltration, synergy with immune checkpoint blockade, PAK1 inhibition, Wnt/β-catenin pathway suppression, P-glycoprotein inhibition, and mitochondrial membrane disruption in cancer cells.
🔗 Ivermectin dosage for cancer treatment — dosing under investigation differs from antiparasitic use. See our full case-series review for details.
Ivermectin occupies a distinctive position: 400+ publications (mostly preclinical), a growing case-series dataset, and an active Phase I/II combination trial. On the NCT05318469 trial specifically, the accurate picture as of the data presented at the 2025 ASCO Annual Meeting is more modest than "positive results" headlines suggest: among 8 evaluable patients, 1 had a partial response, 1 had stable disease, and 6 had disease progression; median progression-free survival was 2.5 months, and the 4-month clinical benefit rate was 37.5%. The investigators' own conclusion was that the ivermectin–balstilimab combination is safe and well tolerated — a Phase I safety readout, not a confirmed efficacy signal. This is worth stating plainly because the trial is frequently cited as evidence of clinical efficacy in a solid tumor when the reported outcome mix does not yet support that characterization.
⚠️ Standard antiparasitic dosing may be inadequate — and inappropriate — for investigational oncology use, and per ASCO's May 2026 Clinical Notice, ivermectin should not be used to treat cancer outside a registered clinical trial. See: Dr. Makis Protocol (2026) for further discussion of dosing debates and licensure context.
15. Benzimidazoles: Fenbendazole / Mebendazole / Albendazole TIER 2 · PHASE II TRIAL (MEBENDAZOLE)
- Cancer types: Multiple cancers (lung, colorectal, prostate, ovarian, glioma — case series); glioma and colorectal cancer (mebendazole clinical trials).
- Human evidence: Mebendazole has the longest human trial record of the three antiparasitics, and the record is mixed. A randomized, placebo-controlled trial (Hegazy et al., 2022; n=40) added mebendazole to standard bevacizumab/FOLFOX4 chemotherapy in metastatic colorectal cancer and found improved response rates and progression-free survival as a chemotherapy adjunct — not a monotherapy replacement. Separately, a randomized trial of mebendazole added to temozolomide in recurrent glioblastoma did not improve survival. Fenbendazole has no completed human cancer trials and achieved public attention primarily through Joe Tippens' self-reported survival from metastatic small-cell lung cancer (NED, 8+ years) and subsequent case-series documentation across 700+ patients.
- Dosage (investigational, not standardized): Mebendazole ~250 mg/day in the colorectal RCT; fenbendazole regimens in case reports range from 222 mg three times weekly (the "Tippens protocol") to daily dosing; albendazole 400 mg twice daily with food.
- Mechanism: Disrupts β-tubulin polymerization, inhibiting cancer-cell mitosis similarly to taxanes/vinca alkaloids; inhibits glucose uptake (GLUT-1); blocks STAT3 signaling; targets cancer stem cells; anti-angiogenic via VEGFR2 inhibition.
Of note, fenbendazole is a veterinary drug without human approval, while mebendazole is the human-approved equivalent and is preferred where a benzimidazole is being considered. Neither should be sourced as a veterinary formulation for human use.
🔗 Read: Fenbendazole vs Mebendazole for Cancer: What Is the Difference?
⚠️ See the Regulatory & Safety Update above — ASCO's May 2026 Clinical Notice applies to fenbendazole use outside a clinical trial. Case reports of drug-induced liver injury have been published in patients self-administering high-dose fenbendazole.
16. High-Dose Intravenous Vitamin C TIER 2 · PHASE I/II TRIALS
The key distinction from earlier negative studies (Mayo Clinic, 1985) is that oral vitamin C does not achieve pharmacologic serum levels — intravenous administration is required for the proposed anticancer effects. The aspirin–vitamin C combination shows synergistic activity in animal models (73% lifespan extension vs. untreated controls; 46% tumor-volume reduction).
⚠️ Contraindicated in G6PD deficiency (risk of hemolysis). Requires specialist administration and monitoring.
17. Disulfiram + Copper TIER 2 · PHASE I/II TRIALS
⚠️ Patients must strictly avoid alcohol — severe cardiovascular reactions can occur. Not suitable for patients with hepatic impairment.
🔗 Related: Disulfiram in APC-Mutated CRC: Precision Oncology Application
18. Itraconazole TIER 2 · PHASE II TRIALS
⚠️ Significant drug interactions, including with statins and cimetidine. Hepatotoxicity risk at high doses — monitor liver function tests regularly.
19. PDE5 Inhibitors (Sildenafil / Tadalafil / Vardenafil) TIER 2 · PHASE I/II TRIALS
⚠️ Absolutely contraindicated with nitrates (risk of severe hypotension). Caution in patients with a history of NAION. Serious cardiovascular side effects are possible.
20. Atovaquone TIER 2 · PHASE I/II TRIALS
Atovaquone is an FDA-approved antimalarial and anti-Pneumocystis drug (brand name Mepron) repurposed for its ability to inhibit mitochondrial Complex III, reducing tumor hypoxia by lowering cancer cells' oxygen consumption. Hypoxic tumor regions are a well-established driver of resistance to radiotherapy and chemotherapy, which is the central rationale for atovaquone's oncology development program.
- ARCADIAN trial (University of Oxford, Cancer Research UK–funded): a Phase I dose-escalation study combining atovaquone with concurrent chemoradiotherapy in locally advanced NSCLC, reaching its planned dose level with a manageable side-effect profile.
- ATOM trial (Oxford, NCT02628080): a companion hypoxia-PET-CT imaging study finding that atovaquone reduced tumor hypoxic volume in NSCLC patients relative to untreated controls, with no atovaquone-related adverse events reported.
- Ovarian and pediatric indications: Phase II evaluation in platinum-resistant ovarian cancer, and combination testing with chemotherapy in pediatric AML (the completed ATACC-AML trial).
Mechanistically, atovaquone functions as a potential radiosensitizer rather than a cytotoxic agent in its own right — a meaningfully different role from the antiparasitic agents discussed above.
21. Niclosamide TIER 2 · PHASE I/II TRIALS
Niclosamide is a chlorinated salicylanilide anthelmintic first marketed for human tapeworm infection in the early 1960s and listed on the WHO Model List of Essential Medicines. The FDA approved it for tapeworm treatment in 1982 (brand name Niclocide) but — unlike ivermectin, mebendazole, and atovaquone — niclosamide is no longer commercially marketed in the United States, even though the historical approval was never formally withdrawn. It remains available in other countries under brand names such as Yomesan.
Proposed anticancer mechanisms
Niclosamide is considered a "pleiotropic" repurposing candidate because it appears to interfere with several oncogenic pathways simultaneously:
- Wnt/β-catenin inhibition: promotes degradation of LRP6, a Wnt co-receptor, blocking downstream β-catenin accumulation — the basis for testing in Wnt-driven cancers such as colorectal cancer and familial adenomatous polyposis (FAP).
- STAT3 inhibition: blocks STAT3 phosphorylation and nuclear translocation, downregulating anti-apoptotic targets such as Mcl-1 and survivin in models including hepatocellular carcinoma.
- NF-κB and Notch signaling: several groups report impaired NF-κB activation (via TAK1/IKK) and Notch signaling, though at least one mechanistic study in colorectal cancer cell lines found no effect on NF-κB or mTOR — the mechanism appears to vary by cancer type rather than acting uniformly.
- Mitochondrial uncoupling: as with its antiparasitic mechanism, niclosamide uncouples mitochondrial oxidative phosphorylation, impairing ATP production in cancer cells.
- Macropinocytosis/nutrient-transport inhibition: more recent work (2023) describes niclosamide acting as a proton channel that blocks macropinocytosis and the amino-acid transporter SLC38A5.
- Androgen receptor splice-variant degradation: in prostate cancer, niclosamide degrades constitutively active AR splice variants such as AR-V7, a resistance mechanism to abiraterone and enzalutamide.
Clinical trials
- Colorectal cancer — NIKOLO trial (NCT02519582, Charité Universitätsmedizin Berlin): a single-arm, open-label Phase II study of niclosamide (2 g/day orally) in metastatic colorectal cancer progressing after standard therapy, built around suppression of the Wnt target gene S100A4.
- FAP chemoprevention (NCT04296851, Yonsei University): a randomized, double-blind, placebo-controlled Phase II trial of niclosamide 650 mg/day for six months, assessing effects on colorectal and duodenal polyp burden.
- Castration-resistant prostate cancer: multiple early-phase combination trials, including a reformulated-niclosamide Phase Ib study with abiraterone/prednisone, a dose-escalation study combining niclosamide with enzalutamide, and a Phase II trial of abiraterone plus niclosamide/prednisone (NCT02807805; listed active but not recruiting as of this update).
- Preclinical combinations: pairing niclosamide with metformin to more completely suppress Wnt and Hippo/YAP signaling in APC-mutated colorectal cancer models.
The bioavailability problem
Niclosamide's biggest translational obstacle is pharmacokinetics, not safety. Designed to act locally against intestinal tapeworms, oral niclosamide is poorly absorbed systemically — the central barrier researchers cite to using standard tablets as a systemic anticancer agent. This has driven reformulation efforts (amorphous solid dispersion, nanoparticle formulations) including the "PDMX1001" product used in some prostate-cancer trials. Trial doses reported above — some considerably higher than the 2 g single-dose antiparasitic regimen — reflect attempts to overcome this bioavailability ceiling, not an established oncology dosing protocol.
Tier 3: Emerging Evidence (Clinical Series / Observational)
These interventions have meaningful human data — case series, observational studies, small clinical trials — combined with strong preclinical rationale, but lack large RCT confirmation and remain under active investigation.
22. Green Tea (EGCG) TIER 3 · EPIDEMIOLOGICAL + MECHANISTIC
A Phase I trial (NCT00516243) targeting women with hormone-receptor-negative stage I–III breast cancer is exploring EGCG's safety and effectiveness, and two additional trials for colorectal cancer (NCT02321969, NCT01360320) are in progress. The potential therapeutic application of EGCG remains restricted by its limited oral bioavailability.
⚠️ High-dose green tea extract may be hepatotoxic in individuals with underlying liver conditions — use with caution and monitor liver function tests.
23. Curcumin (Nanocurcumin) TIER 3 · SMALL CLINICAL TRIALS
⚠️ Curcumin interacts with anticoagulants (warfarin, clopidogrel), some antibiotics, and antidepressants. Nanocurcumin or phospholipid-complex formulations are needed for adequate bioavailability.
24. Berberine TIER 3 · SMALL CLINICAL TRIALS
⚠️ Absolute contraindication with cyclosporine (raises levels dangerously). Monitor blood glucose closely when combining with metformin. May alter metabolism of warfarin, tacrolimus, sedatives, and losartan.
25. Glucose Management, Ketogenic Diet & GLP-1 Agonists TIER 3 · OBSERVATIONAL + METABOLIC ONCOLOGY
- Cancer types: Multiple Warburg-effect-dependent tumors; obesity-related cancers (GLP-1 data).
- Evidence: A 2025 ASCO-presented observational study of 170,030 diabetic patients found GLP-1 receptor agonists associated with a modest 7% lower risk of 14 obesity-related cancers and 8% lower all-cause mortality versus DPP-4 inhibitors. A newer, June 2026 Annals of Oncology analysis extended this to obese, non-diabetic adults (n≈229,000) and found a larger 41% relative reduction in obesity-associated cancer incidence over an average two-year follow-up (with wide variation by subgroup — a 68% reduction in men versus 35% in women, and no statistically significant reduction observed in Black patients), underscoring that this remains an active, evolving evidence base rather than a settled effect size. Separately, observational data support a possible role for ketogenic diets in glioma and NSCLC, and continuous glucose monitor (CGM) studies use post-meal glucose as a tumor-growth proxy.
- Approach discussed in the literature: carbohydrate restriction to <25 g/day (strict keto); a post-meal glucose target below 120 mg/dL via CGM; the Glucose-Ketone Index (GKI) as a metabolic monitoring tool.
- Mechanism: reduces circulating glucose and insulin, potentially starving Warburg-dependent tumor cells; ketone bodies cannot be efficiently metabolized by most cancer cells; reduces IGF-1 signaling; may synergize with fasting-mimicking approaches.
🔗 Related: FLCCC Fasting and Healthy Eating Guide
⚠️ GLP-1 agonists carry their own gastrointestinal, gallbladder, and (rarely) pancreatitis risks, and should be prescribed and monitored by a physician — the cancer-risk data above describes population-level association, not an indication for cancer treatment or prevention.
26. Methylene Blue TIER 3 · SYSTEMATIC REVIEW (PDT) + IN VIVO
- Cancer types: Ovarian (platinum-resistant), colorectal, melanoma, glioblastoma.
- Evidence: Lim 2023 systematic review (photodynamic therapy efficacy in colorectal cancer, carcinoma, melanoma); Da Veiga Moreira 2024 (in vivo ovarian tumor restraint); Makis 2025 (post-surgical breast-cavity clearance; GBM + temozolomide synergy, case-level report).
- Dosage: not yet standardized for oncology use; PDT (Photo-Dynamic Therapy) protocols are center-specific.
- Mechanism: mitochondrial Complex IV enhancer (electron carrier); photosensitizer for PDT, generating singlet oxygen to destroy tumor cells; inhibits mTOR; reduces mitochondrial ROS in normal cells while increasing it in cancer cells.
🔗 Read: Methylene Blue for Cancer: Mechanisms and Clinical Implications
Tier 4: Experimental / Primarily Preclinical
These interventions lack robust human clinical trial data. Some have strong biological rationale and emerging case-report signals. They are listed for completeness and to reflect current integrative-oncology discussion — not as recommended treatments.
27. DMSO (Dimethyl Sulfoxide) TIER 4 · PRECLINICAL + ANECDOTAL
Dr. William Makis summarized the current status in April 2026 by contrasting DMSO's evidence base directly with ivermectin's: in his characterization, DMSO's anticancer use in humans remains essentially undocumented, whereas ivermectin already has 400+ publications, human trials in progress, and dedicated research funding — a gap he described as worth closing through further DMSO research rather than clinical use in the meantime. That contrast captures where DMSO sits today: promising preclinical biology, essentially no human trial evidence, warranting investigation rather than clinical use.
Licensure note: Dr. Makis's Alberta medical license lapsed in 2019, and a March 2026 permanent injunction (upheld on appeal in June 2026) bars him from practicing medicine or using the titles "Dr." or "oncologist." His commentary is presented here as a named public viewpoint in the integrative-oncology discussion, not as a credentialed clinical recommendation. See our Makis Protocol coverage for fuller context.
🔗 Read: DMSO and Cancer: The Overlooked Therapy (OneDayMD Substack)
28. Ashwagandha (Withania somnifera) TIER 4 · PRECLINICAL
⚠️ May affect thyroid hormone levels — monitor if a thyroid condition is present. Potential interactions with immunosuppressants and thyroid medications.
29. Gerson Therapy TIER 4 · HISTORICAL / NO ROBUST CLINICAL TRIALS
The Gerson Therapy occupies a complex position: historically significant, with patient communities reporting subjective benefit, but lacking rigorous clinical evidence, and its intensive regimen makes adherence difficult. Coffee enemas carry real risks including electrolyte disturbance and rare fatalities. If considered at all, it should be supervised by an experienced, Gerson-trained practitioner.
30. Hydralazine (Glioblastoma) TIER 4 · CELL STUDIES ONLY
The originating press release from Memorial Sloan Kettering emphasized this as a starting point for drug-repurposing research, not a clinical treatment. As an already FDA-approved blood-pressure drug, it could in principle enter trials faster than a novel compound — but human evidence is entirely absent at this stage.
Anticancer Nutrition: The Dietary Foundation
Why Diet Belongs in This Evidence Review
Pharmacological interventions — however promising — operate within a metabolic environment shaped entirely by what the patient eats. A repurposed-drug regimen administered alongside a diet of fried food and sugar-sweetened beverages is working against itself. What follows is an evidence-ranked review of dietary interventions, applying the same rigor used for the drug and lifestyle therapies above.
⚠️ If cancer hospitals are still serving ultra-processed meals, that is a real problem. Cancer patients require carefully tailored nutrition to support treatment and recovery. Healthy diets for cancer patients emphasize whole foods rich in fiber, lean proteins, healthy fats, fruits, and vegetables, while limiting ultra-processed foods, fried snacks, and excessive sugar. High-calorie options such as ice cream may occasionally be warranted to maintain weight in patients with poor appetite, but regularly serving nutrient-poor, processed food as a default directly contradicts evidence-based oncology nutrition practice.
1. ACS Guidelines: The Baseline Standard
In 2020, the American Cancer Society published updated diet and physical-activity guidelines for cancer prevention. A healthy eating pattern, per the ACS, emphasizes a variety of vegetables (dark green, red and orange, legumes), whole fruits, and whole grains, while limiting or excluding red and processed meats, sugar-sweetened beverages, and highly processed foods and refined grains.
A 2024 literature review in Nutrients updated the international evidence base, concluding that the Mediterranean diet reduces cancer risk; overnight fasting may contribute to cancer prevention but excessive fasting can harm quality of life; vegetarian and pescetarian diets are associated with lower risks of general and colorectal cancer compared with a carnivorous diet; high heme and total iron intake are linked to increased lung cancer risk; and coffee and tea have a neutral impact on cancer risk.
📌 The WCRF/AICR Cancer Prevention Recommendations (2018) represent the most comprehensive global synthesis. Greater adherence to these recommendations is associated with reduced risk of all cancers combined (BMC Medicine, 2023).
2. Ultra-Processed Foods, Sugar, Preservatives & Insulin Resistance
The evidence linking ultra-processed food to cancer is now robust at the umbrella-review level — the highest tier of epidemiological evidence.
| Evidence Source | Finding |
|---|---|
| Ultra-Processed Food (AACR, 2026) | Linked ultra-processed food to reduced survival after a cancer diagnosis. Sugar, starch, and saturated fat packed into UPF worsen cancer prognosis. |
| Ultra-Processed Food Umbrella Review (BMJ, 2024) | 45 pooled analyses, 9,888,373 participants: direct associations between UPF and 32 health parameters, including cancer, all-cause mortality, and metabolic dysfunction. |
| Insulin Resistance (Nature Communications, Feb 2026) | Insulin resistance linked to a 25% higher risk across 12 cancer types. Strongest signal: uterine cancer (+134% risk). An AI tool was developed to predict insulin resistance and flag cancer risk. |
| Food Preservatives (BMJ, 2026) | French NutriNet-Santé cohort (7.57-year follow-up): higher preservative intake associated with higher overall cancer and breast-cancer rates, independent of age, BMI, activity, smoking, and alcohol. |
| Sugar Umbrella Review (BMJ, 2023) | 8,000+ studies support limiting dietary sugar. Sugar-sweetened soft drinks linked to obesity-related cancers. Cancer cells consume glucose at roughly 200× the rate of normal cells. |
| MGO / Sugar Mechanism (Cell, 2024) | Findings on methylglyoxal (MGO), a reactive sugar metabolite, support reducing sugar intake as a direct mechanism for mitigating cancer risk at the cellular level. |
The food ecosystem is dominated by processed foods and sweetened beverages — see the Top 10 Food & Beverage Companies by Revenue for the scale of the industry. Diets high in processed food, sugar, and unhealthy fats contribute to inflammation and metabolic disorders that fuel the same environment in which cancer thrives.
Key takeaway: avoid sugar, ultra-processed foods, and food preservatives where possible. This is supported by the highest level of epidemiological evidence (umbrella reviews) and endorsed by every major cancer-nutrition guideline.
3. Plant-Based & Mediterranean Diets
Certain plant compounds regulate cancer-protective pathways and activate detoxification systems: sulforaphane (cruciferous vegetables), flavonoids (citrus), polyphenol catechins (green tea), and curcumin (turmeric), according to a 2025 review in the Journal of Nutritional Oncology. A cancer-preventive diet does not need to be fully vegetarian, but should be rich in colorful fruits and vegetables.
| Diet / Food | Evidence | Key Cancers |
|---|---|---|
| Vegetarian / Vegan Diet | Umbrella review (PLOS One, 2024) — 48 reviews & meta-analyses: significantly reduces risk of gastrointestinal and prostate cancer, and associated mortality. | GI, Prostate, Bowel |
| Healthy Plant-Based Diet | BMC Medicine 2022 (n=79,952 men): highest plant-based food intake associated with 22% lower bowel-cancer risk. JAMA Oncology 2022: plant-enriched diet reduces cancer risk. | Colorectal, Bowel |
| Mediterranean Diet + Olive Oil | Meta-analysis of 45 studies (2022): daily olive-oil consumption associated with 31% lower risk of any cancer. Mediterranean diet associated with reduced breast-cancer risk. | Breast, Multiple |
| Cruciferous Vegetables | BMC Gastroenterology (2025): 17 studies, 639,539 participants, 97,595 colon-cancer cases — 17% reduction in colon-cancer risk at 40–60 g/day (~½ cup cooked broccoli). Umbrella review (2022): protective for gastric, lung, endometrial cancers and all-cause mortality. | Colon, Gastric, Lung, Endometrial |
| Quality Matters | Am J Clin Nutr (2023): a healthy plant-based diet is associated with lower pancreatic-cancer risk; an unhealthy plant-based diet with higher risk. Not all plant-based eating is equivalent. | Pancreatic |
⚠️ Nutrients of concern for vegetarians and vegans: vitamin B12 (found only in animal products — deficiency causes anemia and neurological damage), vitamin K2, vitamin D, omega-3 fatty acids, and minerals including iodine, selenium, iron, and zinc. Anyone on a vegan or largely plant-based diet should supplement with B12 and K2 at minimum.
4. Dietary Fiber
An umbrella review in Nutrients (2023) examined 11 large-scale meta-analyses. The conclusion was consistent across cancer types: higher dietary fiber intake tracks with lower risk of several cancers, particularly gastric, esophageal, ovarian, and endometrial tumors.
The mechanisms are relatively clear. For endometrial and ovarian cancers, fiber reduces reabsorption and bioavailability of circulating estrogens, lowering hormonal stimulation of tumor growth. For breast cancer, higher fiber intake tracked with fewer tumor incidences, particularly in postmenopausal women, via the same estrogen-recirculation pathway. Across analyses, fiber also moderates inflammation, a known driver of malignant cell growth.
📌 Optimal intake: a 2019 Lancet publication found the greatest risk reduction with daily fiber intake of 25–29 g/day. Most people in high-income countries consume fewer than 20 g daily. Practical sources: legumes, whole grains, broccoli, berries, apples, oats, lentils, and chia seeds.
5. Fasting, Calorie Restriction, Low-Carb & Ketogenic Diet (Controversial)
⚠️ Label: Controversial — the evidence remains mixed and inconclusive. This topic is included because of its growing interest within integrative oncology, while emphasizing the limitations of the available evidence and the need for clinical caution.
A 2024 Nutrients literature review concluded that overnight fasting and carbohydrate restriction may contribute to cancer prevention, but excessive fasting may harm quality of life. A Japanese study (cited in Korean gastric-cancer guidelines) found low-carbohydrate diets associated with higher risk of colorectal and lung cancer but reduced risk of gastric cancer — illustrating why blanket recommendations are inadequate.
Patient selection matters critically. Underweight patients should not pursue fasting, low-carb, calorie-restriction, or ketogenic approaches. For overweight patients, short-term strategies may be considered, but long-term safety evidence remains mixed, and extreme caloric restriction combined with high-intensity exercise increases cortisol and should be avoided in cancer patients.
The biological case for ketogenic diets rests on the metabolic theory of cancer, most prominently advanced by Prof. Thomas Seyfried (Boston College): cancer cells with defective mitochondria and impaired metabolism can only ferment glucose and glutamine for energy, and ketone bodies cannot be fermented by cancer cells, making a ketogenic metabolic environment theoretically hostile to tumor growth (Nature, 2019). A 2021 review (Curr Issues Mol Biol) describes the ketogenic diet producing an unfavorable metabolic environment for cancer cells and representing a promising adjuvant.
Important distinction: do not conflate reducing added sugar and ultra-processed food with calorie restriction — these are distinct dietary strategies. Limiting added sugar and highly processed food is broadly consistent with established healthy-eating patterns, whereas deliberate calorie restriction requires careful patient selection and further study in cancer patients. For many patients, dietary diversity and metabolic flexibility (the ability to shift between carbohydrate- and fat-derived fuels) may be more practical and sustainable than a strict ketogenic diet. Time-restricted eating or carefully implemented fasting periods may support metabolic flexibility, although safety, feasibility, and clinical benefit require individualized assessment and further research.
Note on glutamine: red meat is among the highest dietary sources of glutamine (~1.2 g per 100 g serving). For glutamine-driven tumors, berberine is discussed as a promising intervention once delivery/bioavailability issues are resolved (Onco, 2025).
🔗 IMA/FLCCC Dietary Guidance: Dietary Interventions in Cancer
6. Meat: Cooking, Processing & Cancer Risk
The cancer risk associated with meat is shaped significantly by how it is processed and cooked, not simply by how much is eaten.
Processed meat is classified as a Group 1 carcinogen by the International Agency for Research on Cancer. Hot dogs, bacon, sausage, deli meat, pepperoni, salami, and jerky contain nitrates and nitrites — preservatives that prevent bacterial growth but trigger formation of N-nitroso compounds (NNOCs), which promote DNA damage, oxidative stress, and inflammation in the colonic mucosa (per a GeroScience meta-analysis). Despite this, nearly half of 2,202 American adults recently polled were unaware that processed meat increases cancer risk, while two-thirds supported warning labels on packaging.
High-heat cooking of any meat — charring, burning, grilling, smoking, or high-temperature pan-searing — generates heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs), which cause genetic mutations in colon and rectal lining cells; a Nutrients study found the same mechanism increases oral-cancer risk.
The broader red-meat–cancer link is less settled. A review in Annals of Internal Medicine noted low certainty of evidence, small effect sizes, and confounding factors (physical inactivity, low fiber intake, gut dysbiosis, obesity), making it methodologically difficult to isolate meat as a direct cause.
💡 A practical strategy sometimes described as "ristoceutics": pairing red meat with fiber-rich vegetables appears to attenuate cancer risk. A Nutrients study found a diet high in red meat but low in fruit and vegetables was associated with increased risk across 15 cancers, while lower meat intake combined with higher vegetable and fruit consumption showed a far less consistent association — the accompanying dish matters.
There is also a protective side to meat. Carnosine, found in high concentrations in animal muscle (especially red meat), reduces viability and growth of colorectal cancer cells as an antioxidant (Oncology Letters). Highly bioavailable heme iron in meat delivers oxygen in ways plant sources cannot efficiently replicate, and the immune and detoxification systems — both critical for cancer defense — depend on protein, of which animal foods remain among the richest sources.
Bottom line: avoid processed meat and high-heat-charred meat; limit unprocessed red meat to moderate quantities; pair all meat with ample vegetables and fiber. Food quality and preparation method matter more than a binary "meat vs. no meat" framing.
7. Coffee & Cancer
Coffee is among the most studied dietary compounds in oncology — PubMed indexes more than 2,500 studies on coffee and cancer — and the overall picture is favorable.
| Evidence | Finding |
|---|---|
| Umbrella review (Nature, 2021) | Coffee consumption inversely associated with liver cancer and skin basal-cell carcinoma. |
| Review of 1,000+ coffee compounds (2023) | Consistent associations between regular coffee intake and reduced risk of liver, endometrial, thyroid, and colorectal cancers. |
| JAMA Oncology (2020) | Regular coffee consumption associated with improved outcomes in non-metastatic colorectal cancer (large observational study nested in a clinical trial). |
| Systematic review (2019, 4 studies) | Weak-to-strong inverse association between coffee and liver cancer; Japanese populations likely to see a decrease in primary liver-cancer risk from regular consumption. |
| ACS 2024 update (Nutrients) | Coffee and tea have a neutral impact on overall cancer risk (confirms safety; no increased risk). |
☕ Practical implication: 3–4 cups of coffee daily is associated with the most consistent cancer-risk-reduction signals. There is no current evidence to restrict coffee in cancer patients. Avoid adding sugar or high-sugar flavored syrups, which would offset any benefit.
🥦 Anticancer Nutrition: Practical Priority Summary
| Category | Guidance |
|---|---|
| ✅ Do prioritize | Cruciferous vegetables (≥40 g/day); colorful whole fruits; legumes and whole grains; oily fish; olive oil; 3–5 cups green tea or coffee daily; 25–29 g dietary fiber/day. |
| ✅ Do adopt | Mediterranean diet pattern; healthy plant-based diet with quality animal protein; B12 + K2 supplementation if plant-based; organic where practical to reduce preservative load. |
| ⛔ Avoid strictly | Ultra-processed foods; sugar-sweetened beverages; food preservatives (especially nitrates/nitrites); charred or smoked meats; excessive red meat without vegetable pairing. |
| ⚠️ Use with caution | Fasting / ketogenic diet (not for underweight patients; mixed evidence; requires medical supervision); calorie restriction (patient selection is critical). |
| 📌 Key principle | Food quality and preparation method matter more than strict dietary categories. A processed vegan diet is worse than a whole-food omnivorous diet. Pair all meals with abundant vegetables. |
Lifestyle Foundation: Stress Reduction, Sleep & Sunshine TIER 4
- Cancer types: most cancer types.
- Evidence: strong indirect evidence linking chronic stress, sleep deprivation, and low vitamin D to cancer incidence and progression; no direct RCTs testing stress reduction as a cancer treatment.
- Techniques: meditation, deep breathing, mindfulness, and nature exposure — 15+ minutes outdoors daily.
- Dosage: 7–9 hours of restorative sleep; sleep disruption suppresses melatonin and natural-killer (NK) cell activity.
- Mechanism: chronic cortisol elevation drives immunosuppression and reduced tumor surveillance; sleep deprivation reduces melatonin and apoptotic signaling; sunshine drives vitamin D synthesis and VDR-mediated cancer-suppression pathways.
Although ranked Tier 4 for lack of direct RCT evidence on oncology outcomes, these three lifestyle factors represent the essential, non-negotiable foundation of any integrative cancer protocol. Their indirect evidence is compelling and their risk profile is close to zero. They should be treated as prerequisites, not optional additions.
Discussion: Where the Field Is Heading
Several clear themes emerge from this evidence-ranked review:
The Tier 1 story is already compelling. Aspirin (in PIK3CA-mutant CRC), metformin, statins, cimetidine, and foundational diet/exercise/lifestyle measures are supported by meta-analyses and guideline updates. These are not "fringe" therapies — they are data-supported, low-cost interventions that most oncology teams do not actively prescribe. The ALASCCA trial has already moved aspirin into NCCN guidelines, and cimetidine's Cochrane-level survival signal in CRC compares favorably with many approved drugs.
The perioperative window is critically underutilized. Propranolol and cimetidine both show their strongest signals in the perioperative context — the days around cancer surgery when immune suppression and stress-hormone surges create metastatic opportunity. Addressing this pharmacologically is low-risk and supported by trial data.
Antiparasitic repurposing is advancing scientifically even as regulators grow more cautious about unsupervised use. Ivermectin and the benzimidazoles already sit in Tier 2 in this framework on the strength of active Phase I/II trials, a Phase II-tested positive mebendazole combination in colorectal cancer, and a large case-series dataset — but the honest state of that Tier 2 evidence is mixed rather than uniformly encouraging: the highest-profile ivermectin combination trial reported more disease progression than response among evaluable patients, and mebendazole's own randomized record includes a negative glioblastoma trial alongside a positive colorectal one. At the same moment this research is advancing, ASCO's May 2026 Clinical Notice has drawn a clear regulatory line against self-directed use outside a trial. Both things are true simultaneously, and this review tries to hold them together rather than picking one narrative.
Metabolic oncology is maturing. Metformin, statins, berberine, glucose restriction, and GLP-1 agonists are converging around a coherent framework: disrupt cancer-cell metabolic dependencies while preserving normal-cell function. The 2025 ASCO diabetic-cohort GLP-1 data and the June 2026 non-diabetic obesity-cohort data, together with the broader insulin/cancer evidence base, are strengthening this approach — though effect sizes vary meaningfully across the studies to date and should not yet be treated as a settled number.
DMSO and other Tier 4 interventions warrant monitored investigation, not dismissal. The biology is interesting in several cases and the compounds are inexpensive and available. What is needed is documentation — peer-reviewed case series, then formal trials. The trajectory that took ivermectin from anecdote to funded Phase I/II research is, in principle, available to other Tier 4 candidates if clinicians document and publish their cases.
Mistletoe's evidence is real but should not be overstated. The strongest recent clinical data are from the Johns Hopkins Phase I IV mistletoe trial (21 patients, 23.8% disease control rate, established Phase II dose), and the much larger subcutaneous RCT literature consistently supports quality-of-life benefit during chemotherapy — but has not demonstrated a survival benefit in placebo-controlled trials.
Low Dose Naltrexone remains the most overlooked Tier 2 intervention. At USD $30–50/month, with a 30-year mechanistic research base, a 2024 systematic review, an active Phase II RCT, and an exceptional safety profile, LDN's absence from standard oncology practice is difficult to justify on evidence grounds alone. The opioid-cancer intersection — specifically the OGF/OGFr cell-cycle-regulation axis — represents a legitimate therapeutic target deserving more clinical attention than it currently receives.
Diet is not optional — it is pharmacological. The 2026 data on insulin resistance (25% increased cancer risk across 12 types), the umbrella review linking ultra-processed food to reduced cancer survival, and the BMJ 2026 preservative study collectively make the case that what a patient eats is not a "lifestyle nicety" but a primary intervention. Cancer centers that continue to serve ultra-processed food as a default patient meal are working against every other treatment on this list — a policy and systems question that deserves attention from hospital administrators, not just oncologists.
📋 Regulatory & Safety Update (2026): In May 2026, ASCO issued a formal Clinical Notice stating there is no robust, peer-reviewed clinical evidence that ivermectin or fenbendazole is safe or effective for treating any human malignancy, and strongly cautioned against using either drug to treat cancer — or as an adjunct to established cancer therapy — outside the regulatory safeguards of a registered clinical trial, citing an "unacceptable risk" from unproven benefit combined with documented toxicity and drug-interaction potential. This notice does not extend to mebendazole's FDA-approved antiparasitic indication, nor does it address the many other agents in this review (aspirin, metformin, statins, etc.), which sit on a different evidence and regulatory footing entirely. Readers considering ivermectin, fenbendazole, or any experimental agent discussed below should raise it directly with their treating oncologist rather than self-sourcing veterinary formulations.
Frequently Asked Questions
Is drug repurposing an approved cancer treatment?
No single "drug repurposing" pathway is an approved treatment. Some individual repurposed drugs have approved indications for specific cancers under specific conditions (BCG in bladder cancer, TTF in glioblastoma and mesothelioma), and some have strong supporting evidence for a defined subgroup (aspirin in PIK3CA-mutant colorectal cancer, now reflected in NCCN guidance). Most of the agents in this review remain investigational and should only be used within a clinical trial or under direct oncologist supervision.
Which repurposed drugs have the strongest evidence?
Aspirin (in PIK3CA-pathway-mutant colorectal cancer), metformin, statins, and cimetidine have the strongest human evidence in this review — each supported by RCTs, meta-analyses, or guideline adoption, rather than case series alone.
Can I add a repurposed drug to my cancer treatment on my own?
This review recommends against it. Even low-risk-seeming agents can interact with chemotherapy, radiotherapy, or other medications, and several entries above carry specific contraindications. Any interest in a repurposed drug should be raised directly with the treating oncology team.
Does diet matter as much as drug therapy?
Diet quality is now supported by umbrella-review-level evidence — the same evidentiary tier as the strongest pharmacological findings in this review — for its association with cancer risk and, in some data, cancer survival. It is best understood as a foundational, parallel intervention rather than a replacement for standard treatment.
Using AI to Personalize This Framework
Because this review necessarily generalizes across cancer types, readers increasingly use AI assistants such as Claude, ChatGPT, Gemini, or Perplexity to help apply it to their own situation — for example, asking an assistant to cross-reference a specific cancer type and current medication list against the Tier 1–2 entries above, or to summarize the ASCO notice in plain language for a family conversation. This can be a useful starting point for organizing questions, but AI assistants do not have access to a patient's full chart, cannot verify drug interactions with the same rigor as a pharmacist or oncologist, and can occasionally state outdated or incorrect information with confidence. Any AI-assisted summary of this material should be treated as a discussion draft to bring to the oncology team, not as a personalized medical recommendation in itself.
Conclusion
Theoretically, repurposed drugs can partially alleviate the shortage of new drugs and resistance to existing chemotherapeutics. For patients with advanced disease or chemotherapy resistance who lack alternative treatment options, combination therapy is a promising and valuable avenue. Combining repurposed drugs with approved anticancer agents can achieve synergy and improve therapeutic effectiveness and safety.
Because of the multiple mechanisms of resistance and the complex oncogenic signaling pathways involved in cancer, monotherapy may be relatively ineffective; this may explain why few repurposed drugs are used as monotherapy in current practice, and why, in the era of precision medicine, combination strategies are more promising. Drug combinations typically target multiple mechanisms — downstream off-target effects, parallel pathways, or compensatory signaling — and as molecular profiling advances, non-oncology drugs capable of targeting multiple cancer hallmarks and the tumor microenvironment could become a valuable complement to personalized, precision treatment.
This review offers a framework for that combination opportunity. Start with Tier 1: aspirin for PIK3CA-mutant CRC, exercise, metformin, statins, and cimetidine for colorectal cancer — evidence-backed, low-cost, and underutilized. Add Tier 2 interventions — BCG (bladder cancer), TTF (glioblastoma, mesothelioma), hyperthermia, mistletoe, LDN, propranolol, vitamin D, omega-3, IV vitamin C, melatonin — guided by cancer type and patient context, while treating ivermectin and the benzimidazoles as investigational agents to discuss with, not substitute for, an oncology team, in light of ASCO's May 2026 guidance. Consider Tier 3 repurposed candidates only under physician supervision with clear monitoring. Treat Tier 4 interventions as experimental: potentially valuable directions for future research, currently unproven in humans.
Underpin all of this with an anticancer nutritional foundation: eliminate ultra-processed foods, sugar-sweetened beverages, and processed meats; emphasize cruciferous vegetables, dietary fiber (25–29 g/day), olive oil, and whole plant foods; and apply ketogenic or fasting strategies only under appropriate clinical supervision. The evidence for diet quality in cancer outcomes is now at umbrella-review level — the same tier as the strongest pharmacological evidence — and deserves the same clinical priority.
To find integrative oncologists who might guide this process, see our Integrative Oncologist Directory.
Key References & Further Reading
- ALASCCA Trial (NCT02647099) — Aspirin in PIK3CA-pathway-altered CRC. Presented 2025 ASCO GI Cancers Symposium; Martling et al., NEJM, 2025. [Summary]
- Cochrane Review — Cimetidine adjuvant therapy in colorectal cancer, 2012 (6 RCTs, 1,229 patients).
- ESHO Multicenter Trial — Hyperthermia + radiotherapy in metastatic melanoma. [Source]
- COMPIT Trial — Perioperative propranolol + etodolac in CRC. Eur J Surg Oncol, 2023.
- Propranolol systematic review (31 studies, 7 RCTs). PMC, 2025. [Source]
- NCT05318469 — Phase I/II ivermectin + balstilimab in metastatic TNBC, Cedars-Sinai. Data presented at the 2025 ASCO Annual Meeting: 8 evaluable patients (1 PR, 1 SD, 6 PD); median PFS 2.5 months; 4-month clinical benefit rate 37.5%; concluded safe and well tolerated. [Trial]
- ASCO Clinical Notice — Recommending Against Ivermectin and Fenbendazole for Cancer Treatment, Outside of Clinical Trials. May 2026. [ASCO]
- De Castro et al. Ivermectin in refractory pediatric AML. Anticancer Res, 2020. [PubMed]
- Ishiguro et al. Ivermectin case series, 2022. [PubMed]
- Hegazy et al. Mebendazole added to bevacizumab/FOLFOX4 in metastatic colorectal cancer: randomized, placebo-controlled trial (n=40). 2022.
- Cardiff University — Aspirin and cancer mortality. Br J Cancer, 2023. [Source]
- Aspirin and digestive-tract cancers meta-analysis. Annals of Oncology, 2020.
- High-dose vitamin C review (150+ studies). J Pharmacol Sci, 2026. [Source]
- Fan et al. IV vitamin C dosing (1.5 g/kg/day), 2023.
- Lim. Methylene-blue-mediated PDT — systematic review, 2023. [PMC]
- Da Veiga Moreira et al. Methylene blue in ovarian cancer, 2024. [PMC]
- Matsumoto et al. Cimetidine 10-year survival in CRC. Br J Cancer, 2002.
- Marik PE. Cancer Care, 2nd Edition. FLCCC/IMA Health. [imahealth.org]
- Integrative naturopathic treatment + mEHT in CRC (n=131). Integrative Medicine and Health, 2025.
- Nature — Drug repurposing in cancer, 2024. [Source]
- Top 10 Cancer-Fighting Supplements — Cancer Advisor
- Fenbendazole vs Mebendazole for Cancer [OneDayMD]
- Enhanced Ivermectin + Mebendazole 16-Week Protocol (OneDayMD Substack)
- ACS Diet and Physical Activity Guidelines for Cancer Prevention, 2020.
- ACS Nutrition and Physical Activity Guideline for Cancer Survivors, 2022.
- Nutrients literature review — international cancer dietary guidelines update, 2024.
- AACR — Ultra-processed foods linked to reduced survival after cancer, 2026.
- Nature Communications — Insulin resistance and 12 cancer types (+25% risk). University of Tokyo / Taichung Veterans General Hospital, February 2026.
- BMJ — Food preservatives and cancer risk. NutriNet-Santé cohort, 7.57-year follow-up, 2026.
- BMJ Umbrella Review — Ultra-processed food and 32 adverse health parameters. 45 pooled analyses, 9,888,373 participants, 2024.
- BMJ Umbrella Review — Dietary sugar and cancer risk. 8,000+ studies, 2023.
- Cell — Methylglyoxal (MGO) and sugar-driven cancer-risk mechanisms, 2024.
- PLOS One — Vegetarian/vegan diet and cancer-risk reduction. 48 reviews, 2024.
- JAMA Oncology — Plant-enriched diet and cancer risk, 2022.
- BMC Medicine — Healthy plant-based diet and bowel cancer (n=79,952), 2022.
- Am J Clin Nutr — Healthy vs. unhealthy plant-based diet and pancreatic-cancer risk, 2023.
- BMC Gastroenterology — Cruciferous vegetables and colon-cancer risk: 17 studies, 639,539 participants, 17% risk reduction, 2025.
- Umbrella Review — Cruciferous vegetable intake: gastric, lung, endometrial cancer, 2022.
- Meta-analysis — Olive-oil consumption and 31% lower risk of any cancer. 45 studies, 2022.
- Nutrients — Dietary fiber and cancer risk: umbrella review of 11 meta-analyses, 2023.
- The Lancet — Dietary fiber intake of 25–29 g/day and cancer-risk reduction, 2019.
- Nutrients — Low-carbohydrate diet and cancer risk (Japanese study), 2024.
- Curr Issues Mol Biol — Ketogenic diet antitumor mechanisms, 2021.
- Nutrients — Red meat, cooking methods, and cancer risk, 2024.
- GeroScience — Nitrates, nitrites, and N-nitroso compounds in processed meat (meta-analysis).
- Oncology Letters — Carnosine in red meat and colorectal cancer cell viability.
- Annals of Internal Medicine — Red meat and cancer: low-certainty evidence review.
- Nature — Coffee umbrella review: liver cancer and basal-cell carcinoma, 2021.
- JAMA Oncology — Coffee and non-metastatic colorectal-cancer outcomes, 2020.
- Systematic review — Coffee and primary liver cancer (4 studies), 2019.
- Review of 1,000+ coffee compounds — liver, endometrial, thyroid, colorectal cancer risk reduction, 2023.
- Journal of Nutritional Oncology — Plant compounds and cancer-protective pathways review, 2025.
- IMA Health — Dietary Interventions in Cancer. [imahealth.org]
- BMC Medicine — WCRF/AICR adherence and reduced cancer risk, 2023.
- Systematic review — low-dose naltrexone in cancer (16 studies). Cureus, 2024. [PMID 38966634]
- NCT04401579 — Phase II RCT: low-dose naltrexone + alpha-lipoic acid in pancreatic cancer. [ClinicalTrials.gov]
- Zagon IS, McLaughlin PJ. Opioid growth factor (OGF) and the OGFr receptor axis in cancer biology. Penn State University; 30+ years of mechanistic research.
- LDN Research Trust — clinical evidence database. [ldnresearchtrust.org]
- EF-14 Trial — Tumor Treating Fields + temozolomide in newly diagnosed GBM. JAMA, 2015; five-year OS update, 2017. [PMID 26670971]
- EF-11 Trial — TTF vs. chemotherapy in recurrent GBM (non-inferior, superior tolerability). JAMA, 2012.
- STELLAR Trial — TTF + pemetrexed/platinum chemotherapy in malignant pleural mesothelioma (n=80, Phase 2 single-arm). Median OS 18.2 vs. 12.1 months (historical control). The Lancet Oncology, 2019/2020. NCT02397928. [Annals of Oncology final results]
- Novocure — PANOVA-3 (pancreatic), LUNAR (NSCLC), INNOVATE-3 (ovarian) trial pipeline. [novocure.com]
- Paller CJ, Wang L, Fu W, et al. Phase I trial of intravenous mistletoe extract in advanced cancer. Cancer Research Communications, 2023;3(2):338–346. doi:10.1158/2767-9764.CRC-23-0002. [PMID 36860652]
- Systematic review — mistletoe extracts in cancer (30 datasets, 26 publications). BMC Complement Med Ther, 2020. [PMC7370416]
- Mavromatis et al. GLP-1 receptor agonists and 14 obesity-related cancers in diabetic patients (n=170,030). Presented 2025 ASCO Annual Meeting, Abstract 10507. [ASCO]
- Dai H, et al. GLP-1 receptor agonists and cancer risk in nondiabetic adults with obesity (n≈229,000). Annals of Oncology, June 2026.
- Marik PE. Why Randomized Controlled Trials Are Poorly Suited to Testing Repurposed Drugs and Nutraceuticals in Cancer. 2026. [Substack]
.png)
.png)
Comments
Post a Comment